Brivaracetam in Refractory Epilepsy: Mechanism, Tolerability, and Clinical Positioning

Area of Science:

• Neurology
• Pharmacology

Background:

• Epilepsy is a prevalent neurological disorder with limited treatment options.
• Current antiseizure medications (ASMs) often fail to control seizures and have significant adverse events.
• Drug-drug interactions (DDIs) are common with multiple ASM therapies for refractory epilepsy.

Purpose of the Study:

• To review the preclinical and clinical evidence for brivaracetam (BRV).
• To provide an overview of BRV's pharmacological properties, safety, and efficacy.
• To assess BRV's therapeutic relevance in managing refractory epilepsy.

Main Methods:

• This is a narrative review synthesizing existing preclinical and clinical data.
• Literature search on brivaracetam's mechanism of action, pharmacokinetics, and pharmacodynamics.
• Analysis of clinical trial data and post-marketing surveillance for safety and efficacy.

Main Results:

• Brivaracetam (BRV) selectively targets synaptic vesicle protein 2A with high affinity and superior brain penetration compared to levetiracetam.
• BRV demonstrates potent anticonvulsant activity with a faster onset of action.
• Reported adverse events for BRV are generally mild, transient, and manageable, with minimal impact on cytochrome P450 and P-glycoprotein, reducing DDI risk.

Conclusions:

• Brivaracetam (BRV) presents a promising option for refractory epilepsy due to its efficacy, favorable safety profile, and reduced potential for drug-drug interactions.
• BRV monotherapy shows potential for good tolerability, high retention rates, and improved seizure control.
• BRV is considered a valuable supplemental therapy for refractory focal seizures, enhancing patient quality of life.